VERA

Vera Therapeutics Inc

30.98

Oct 30 • 3:59 PM ET +0.45 (1.47%)

30.37

Aftermarket • 7:30 PM ET -0.61 (-1.97%)

Healthcare Biotechnology USA Mid NASD

Peers: TVTX VRTX JBIO CLYM AUPH MAZE NVS ZBIO IMVT ARGX

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA DFAS FESM

Scroll to Statements

Index	RUT
Market Cap	2.23B
Enterprise Value	1.81B
Income	-401.89M
Sales	0.00M
Book/sh	5.67
Cash/sh	6.93
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	249
IPO	May 14, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.47
P/C	4.47
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.65
Current Ratio	10.65
Debt/Eq	0.18
LT Debt/Eq	0.18
Option/Short	Yes / Yes

EPS (ttm)	-5.87
EPS next Y	-4.27
EPS next Q	-1.62
EPS this Y	-34.13%
EPS next Y	31.71%
EPS next 5Y	49.91%
EPS past 3/5Y	-11.65% -13.19%
Sales past 3/5Y	- -
EPS Y/Y TTM	-63.94%
Sales Y/Y TTM	-
EPS Q/Q	-27.01%
Sales Q/Q	-
Earnings	Nov 05 AMC
EPS/Sales Surpr.	3.54% -

Insider Own	18.81%
Insider Trans	-0.88%
Inst Own	98.56%
Inst Trans	8.46%
ROA	-72.32%
ROE	-91.75%
ROIC	-83.21%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	5.96%
SMA50	-3.19%
SMA200	-16.17%
Trades

Shs Outstand	71.96M
Shs Float	58.51M
Short Float	23.22%
Short Ratio	6.36
Short Interest	13.59M
52W High	56.05 -44.73%
52W Low	23.05 34.40%
Volatility	5.09% 5.70%
ATR (14)	1.72
RSI (14)	52.80
Beta	1.05
Rel Volume	0.51
Avg Volume	2.14M
Volume	1,083,624

Perf Week	10.68%
Perf Month	-0.03%
Perf Quarter	-3.88%
Perf Half Y	-11.99%
Perf YTD	-38.82%
Perf Year	4.42%
Perf 3Y	186.59%
Perf 5Y	60.10%
Perf 10Y	-
Recom	1.29
Target Price	73.79
Prev Close	30.53
Price	30.98
Change %	1.47%

Consensus

Strong Buy

Avg. Price Target

$73.79

Implied Upside

+138.2%

Analysts14incl. previous ratings

Rating Distribution12 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 12, 2026	Initiated	LLeerink Partners	Market Perform	$34	+9.7%
Mar 11, 2026	Upgrade	WWolfe Research	Peer Perform → Outperform	$88	+184.1%
Oct 16, 2025	Initiated	BBofA Securities	Buy	$48	+54.9%
Aug 04, 2025	Downgrade	WWolfe Research	Outperform → Peer Perform
May 05, 2025	Resumed	HH.C. Wainwright	Buy	$75	+142.1%
Feb 04, 2025	Initiated	WWolfe Research	Outperform	$49	+58.2%
Jan 28, 2025	Initiated	GGoldman	Buy	$58	+87.2%
Nov 21, 2024	Initiated	WWells Fargo	Overweight	$70	+126.0%
Oct 16, 2024	Initiated	BScotiabank	Sector Outperform
Jan 25, 2024	Initiated	OOppenheimer	Outperform	$26	-16.1%
Jan 08, 2024	Initiated	CCantor Fitzgerald	Overweight
Dec 18, 2023	Initiated	RRaymond James	Outperform	$29	-6.4%
Nov 10, 2023	Upgrade	JJefferies	Hold → Buy	$18 → $26	-16.1%
Aug 16, 2023	Initiated	GGuggenheim	Buy	$27	-12.8%
Jan 04, 2023	Downgrade	WWedbush	Outperform → Neutral	$33 → $8	-74.2%
Jan 04, 2023	Downgrade	JJefferies	Buy → Hold	$32 → $6	-80.6%
Jul 12, 2022	Initiated	JJP Morgan	Overweight	$35	+13.0%
May 02, 2022	Initiated	HH.C. Wainwright	Buy	$35	+13.0%
Apr 19, 2022	Initiated	WWedbush	Outperform	$32	+3.3%

Oct-28-26 09:39PM	Vera Therapeutics Faces A Cash-Burn Test As Losses Widen And Early Revenue Enters The Model (Earnings Whispers)
Oct-22-26 10:05AM	Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine (GlobeNewswire) -6.89%
Oct-20-26 08:00AM	Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast (GlobeNewswire)
Oct-02-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:24AM	Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 (GlobeNewswire)
09:51PM	Loading…
Sep-15-26 09:51PM	Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run Here Are The Stocks And Catalysts To Watch Next (Stocktwits) -5.64%
12:39PM	Vera set up for full approval for Trutakna in IgAN with Phase III win (Clinical Trials Arena)
12:03PM	Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results (Barrons.com)
10:33AM	Vera Stock Slides Despite Positive Phase 3 Results (Schaeffer's Research)
09:37AM	Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints (InvestorsHub)
09:08AM	VERA Stock Jumps 16% Premarket Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4 (Stocktwits)
06:30AM	Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy (GlobeNewswire)
Sep-04-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-26 07:30AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-26 04:05PM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
04:05PM	Loading…
Aug-07-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-10-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-09-26 08:00AM	Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner (GlobeNewswire)
Jul-07-26 02:43PM	?? Under the Radar: Vera Stock Jumps as Kidney-Disease Drug Approved by FDA (The Wall Street Journal) +7.05%
02:33PM	VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval Retail Sees The Move As Catalyst For Vera Therapeutics (Stocktwits)
12:37PM	Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy (GlobeNewswire)
03:47AM	Vera Therapeutics wins FDA nod for closely watched kidney disease drug (BioPharma Dive)
Jul-06-26 09:10AM	Vera Therapeutics Shares Climb Ahead of FDA Decision on Atacicept (VERA) (InvestorsHub)
08:19AM	Scilex, Vera Therapeutics rise premarket; Strategy gains (Investing.com)
06:53AM	VERA Stock Rallies Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug Retail Sees 35% Potential Upside (Stocktwits)
Jun-05-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-26 12:51PM	Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment (Stocktwits) -7.90%
07:00AM	Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy (GlobeNewswire)
May-08-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-26 07:30AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
07:30AM	Loading…
May-04-26 07:30AM	Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference (GlobeNewswire)
Apr-10-26 04:30PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.04%
Mar-27-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-26 07:30AM	Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer (GlobeNewswire)
Mar-06-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-26 09:00AM	Vera Therapeutics Appoints Christopher Hite to Board of Directors (GlobeNewswire)
Feb-26-26 07:30AM	Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 08:00AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-18-26 07:39PM	Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief Appointment (Insider Monkey)
Feb-16-26 12:23PM	Atacicept's Potential Approval Drives Favorable Views on Vera Therapeutics (VERA) (Insider Monkey)
Feb-07-26 11:35AM	Vera Therapeutics, Inc. (VERA): A Bull Case Theory (Insider Monkey)
Feb-06-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.23%
Jan-30-26 12:24AM	Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential? (Insider Monkey)
Jan-28-26 07:30AM	Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer (GlobeNewswire)
Jan-23-26 11:09AM	Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns (Insider Monkey)
Jan-15-26 11:35AM	Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept (Insider Monkey)
Jan-14-26 09:55AM	Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High? (Zacks)
Jan-09-26 01:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-26 07:30AM	Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-26 07:41PM	Why Vera Therapeutics Stock Zoomed Higher Today (Motley Fool)
07:30AM	Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy (GlobeNewswire)
Dec-09-25 08:57PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire)
Dec-08-25 04:01PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Dec-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.37%
Dec-02-25 07:42PM	Why Vera Therapeutics Stock Rocked the Market on Tuesday (Motley Fool) +12.88% +10.77%
01:09PM	Stock Market Today: MongoDB, Boeing, and Intel Define Tuesday Trade As Market Bounces Back From Post-Thanksgiving Blues (TheStreet)
Nov-26-25 07:45PM	Why Vera Therapeutics Stock Crushed it Today (Motley Fool) +13.25%
04:05PM	Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors (GlobeNewswire)
Nov-24-25 07:25AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-18-25 02:20PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-16-25 10:14PM	H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth (Insider Monkey)
Nov-14-25 09:01AM	Yale University's Strategic Investment in Vera Therapeutics Inc: A 32.26% Portfolio Stake (GuruFocus.com)
Nov-10-25 07:29AM	Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) +14.72%
Nov-07-25 06:27PM	Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy (GlobeNewswire)
04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:51AM	Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine (GlobeNewswire)
Nov-05-25 07:29AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 08:00AM	Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET (GlobeNewswire)
Oct-20-25 11:08PM	BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating (Insider Monkey)
Oct-17-25 09:12AM	Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 (GlobeNewswire)
Oct-10-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.46%
Aug-26-25 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) +5.62%
Aug-08-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 07:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:35AM	Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 07:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 08:07AM	Millions in Insider Buying Point to These 2 Stocks Heres What It Could Signal (TipRanks)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:02AM	Biotech Stock Vera Is Slumping After Monster Gain (Barrons.com) -25.89%
07:49AM	Vera Therapeutics stock sinks following competitors successful trial (Investing.com)
Jun-04-25 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-25 06:30AM	Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans (GlobeNewswire)
02:22AM	Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 06:30AM	Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy (GlobeNewswire) +67.49%
04:51AM	Vera drug scores in closely watched study in rare kidney disease (BioPharma Dive)
May-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-25 08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -13.79%
Apr-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.76%
02:51PM	Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch (Benzinga)
Apr-03-25 08:00AM	Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN (GlobeNewswire)
Mar-11-25 04:28PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:00AM	Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.91%
Feb-26-25 08:25AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.66%
Jan-14-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 07:00AM	Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor (GlobeNewswire) -6.08%
Jan-07-25 04:05PM	Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 06:29PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fordyce Marshall	PRESIDENT AND CEO	Sep 15 '26	Option Exercise	2.90	18,500	53,591	253,744	Sep 17 04:28 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 15 '26	Sale	37.00	18,500	684,500	235,244	Sep 17 04:28 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Sep 11 '26	Option Exercise	3.94	5,000	19,698	80,754	Sep 14 04:28 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 02 '26	Option Exercise	2.90	18,500	53,591	253,744	Sep 04 04:15 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 02 '26	Sale	35.12	18,500	649,642	235,244	Sep 04 04:15 PM
MARSHALL FORDYCE	Director	Sep 02 '26	Proposed Sale	34.23	64,750	2,216,392		Sep 02 04:32 PM
Fordyce Marshall	PRESIDENT AND CEO	Jul 07 '26	Sale	42.30	46,250	1,956,187	151,994	Jul 09 04:45 PM
Fordyce Marshall	PRESIDENT AND CEO	Jun 23 '26	Sale	37.93	18,500	701,769	198,244	Jun 24 04:55 PM
MARSHALL FORDYCE	Director	Jun 23 '26	Proposed Sale	38.43	74,000	2,843,820		Jun 23 04:29 PM
Fordyce Marshall	PRESIDENT AND CEO	May 12 '26	Sale	36.74	18,500	679,747	216,744	May 13 04:26 PM
MARSHALL FORDYCE	Director	May 12 '26	Proposed Sale	36.61	18,500	677,285		May 12 04:33 PM
Fordyce Marshall	PRESIDENT AND CEO	Apr 14 '26	Sale	44.05	22,951	1,011,051	235,244	Apr 15 04:57 PM
MARSHALL FORDYCE	Director	Apr 14 '26	Proposed Sale	43.71	22,951	1,003,188		Apr 14 04:33 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Mar 13 '26	Option Exercise	3.94	10,000	39,396	75,754	Mar 16 06:52 PM
Brenner Robert	Chief Medical Officer	Feb 23 '26	Sale	41.98	2,151	90,307	50,947	Feb 25 08:01 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Feb 23 '26	Sale	41.98	3,117	130,864	64,722	Feb 25 08:00 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Feb 23 '26	Sale	41.98	4,949	207,778	114,181	Feb 25 07:59 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 23 '26	Sale	41.98	16,925	710,578	257,163	Feb 25 07:58 PM
JOHNSON DAVID LEE	Chief Operating Officer	Feb 23 '26	Sale	41.98	2,579	108,276	45,727	Feb 25 07:57 PM
Turner William D.	Chief Regulatory Officer	Feb 23 '26	Sale	41.98	2,187	91,819	45,313	Feb 25 07:56 PM
Skelton Laurence Matthew	Chief Commercial Officer	Feb 23 '26	Sale	41.98	1,582	66,419	64,218	Feb 25 07:53 PM
LAURENCE SKELTON	Officer	Feb 23 '26	Proposed Sale	42.03	1,800	75,663		Feb 23 04:44 PM
WILLIAM DONALD TURNER	Officer	Feb 23 '26	Proposed Sale	42.03	2,600	109,291		Feb 23 04:42 PM
SEAN GRANT	Officer	Feb 23 '26	Proposed Sale	42.03	5,700	239,600		Feb 23 04:41 PM
ROBERT BRENNER	Officer	Feb 23 '26	Proposed Sale	42.03	2,500	105,088		Feb 23 04:39 PM
DAVID L JOHNSON	Officer	Feb 23 '26	Proposed Sale	42.03	2,900	121,902		Feb 23 04:31 PM
MARSHALL FORDYCE	Officer	Feb 23 '26	Proposed Sale	42.03	16,600	697,781		Feb 23 04:29 PM
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 17 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Sale	50.08	10,000	500,767	22,500	Dec 17 04:05 PM
ENRIGHT PATRICK G	Director	Dec 11 '25	Buy	42.50	5,882	249,985	5,882	Dec 15 08:07 PM
WILLIAM TURNER	Officer	Dec 15 '25	Proposed Sale	49.80	10,000	498,000		Dec 15 04:17 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 10 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Sale	45.31	10,000	453,053	22,500	Dec 10 04:05 PM
WILLIAM TURNER	Officer	Dec 08 '25	Proposed Sale	44.90	10,000	449,000		Dec 08 04:41 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 04 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Sale	40.00	10,000	400,000	22,500	Dec 04 04:05 PM
WILLIAM TURNER	Officer	Dec 03 '25	Proposed Sale	37.25	10,000	372,500		Dec 03 04:31 PM
Carter Jason S	Chief Legal Officer	Nov 21 '25	Sale	27.82	3,864	107,498	49,136	Nov 25 04:05 PM
Carter Jason S	Officer	Nov 21 '25	Proposed Sale	27.87	3,864	107,690		Nov 24 09:22 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 13 '25	Option Exercise	3.94	10,000	39,396	57,839	Nov 13 08:57 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 11 '25	Sale	29.06	15,000	435,874	47,839	Nov 13 08:57 PM

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

FounderDr. Marshall W. Fordyce M.D.

Chief Financial OfficerMr. Sean P. Grant M.B.A.

Chief Opearating OfficerMr. David L. Johnson M.B.A.

Chief Medical OfficerDr. Robert M. Brenner M.D.

Senior VP of Finance & Chief Accounting OfficerMr. Joseph R. Young M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VERA

Vera Therapeutics Inc

Upgrade your Finviz experience